CNEN

Search

Welcome to Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.!

Copyright: Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.!   京ICP备19006400号-1​     Powered by 300.cn

Links:

  • Six clinical trials on MSCs approved by US FDA
    Six clinical trials on MSCs approved by US FDA
  • One of the few companies manufacturing both hMSC and hNSC
    One of the few companies manufacturing both hMSC and hNSC
  • First FDA-approved clinical trial using stem cells to treat Alzheimer’s
    First FDA-approved clinical trial using stem cells to treat Alzheimer’s
  • MSCs approved as a treatment of AMI in Kazakhstan
    MSCs approved as a treatment of AMI in Kazakhstan
  • Producing clinical-grade stem cells with strong activity in large scale
    Producing clinical-grade stem cells with strong activity in large scale
  • SCF activity preserved through patented technology for 3 years
    SCF activity preserved through patented technology for 3 years
<
>
Search
Search

 

In 2018, Yonghe Qihang Fund initiated by Jiuzhitang forged partnership with Stemedica Cell Technologies, Inc. by investing in the company, and founded Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. as the sole China recipient of stem cell technologies developed by Stemedica.

Jiuzhitang Maker will bring in Stemedica’s leading stem cells manufacturing platform for clinical-phase uses, and receive Stemedica’s technologies that are core to the large-scale, standardized and trackable manufacture of stem cell products, thus filling such a gap existing in China practices of stem cells production...........

About Us

In the US, Stemedica and its partners have launched 8 clinical trials using stem cells to treat ischemic stroke, skin photoaging, non-ischemic chronic heart failure, Alzheimer’s disease, traumatic brain injury, heart failure requiring LVAD, acute myocardial infarction and lung injury caused by COVID-19. Trials on ischemic stroke and chronic heart failure have completed Phase IIa and published many high level academic papers, while the one on Alzheimer’s is the first US study with approval to treat this debilitating disorder using stem cells. In addition, Stemedica has 11 clinical studies in progress in Switzerland, Kazakhstan, Mexico, China, etc. In particular, the Kazak study treating acute heart failure with Stemedica manufactured it-hMSCs has completed, rendering the product being approved and listed by the Ministry of Health of Kazakhstan as a therapy to this disease in September 2018. 

 


Clinical Indications

Chronic heart failure

Acute myocardial infarction

 

Acute myocardial infarction is myocardial necrosis caused by acute, persistent ischemia and hypoxia in...

Skin aging is a series of complex biological changes that involve both endogenous and  ...

 

Cutaneous photoaging

Traumatic brain/spinal injury

 

Traumatic brain/spinal injury is a penetrating injury mainly caused by traffic accidents, work...

Alzheimer's disease, commonly known as senile dementia, is a common neurodegenerative ...

 

Alzheimer's disease

 

Chronic heart failure

Chronic heart failure lies in the end stage of development of many cardiovascular diseases...

Cerebral stroke

 

Commonly known as apoplexy, cerebral stroke is the second most common cause of death and...

Dr. Nikolai Tankovich
Dr. Nikolai Tankovich
Dr. Tankovich holds a Master of Science degree in Plasma Physics from Moscow University, an M.D. from Semashco Medical University (Moscow), and a Ph.D. in BioPhysics from Lomonosov Moscow University. He is a recognized innovator, researcher and educator for laser applications in medicine, cancer vaccines, stem cell therapies and other medical related disciplines. As founder and director of several corporations, Dr. Tankovich has more than 100 US and other foreign patents issued and pending, and has published over 60 articles on well-known academic journals.
Dr. Alex Kharazi
Dr. Alex Kharazi
Dr. Kharazi finished Medical School in 1978 in Kiev, Ukraine, where he earned his medical degree in internal medicine and pathology. From 1978 to 1981, he was a post-doctoral fellow at the Kiev Institute of Gerontology. Dr. Kharazi was one of the first to discover the inhibitory effects of old thymus in mice and later published over 30 papers on this subject. He is a faculty member at the University of Southern California in Los Angeles, and a named inventor of 8 US patents and various foreign patents.
Dr. Lev Verkh
Dr. Lev Verkh
Dr. Verkh has directed national and multi-national Phase I, II, III and IV clinical trials in such areas as cardiology, oncology, neurology, peripheral vascular diseases, hematology, blood disorders and imaging methods. Through his efforts and the efforts of his teams, he has received FDA approval for several products that are currently on the market. Under his leadership, Stemedica obtained several INDs for clinical trials in the United States and emergency INDs from the FDA.

Advisors

Jiuzhitang Maker is supported by global expertise in areas of stem cells research and development of clinical programs on pharmaceuticals. Dr. Nikolai Tankovich is a recognized innovator, researcher and educator for laser applications in medicine, cancer vaccines, stem cell therapies and other medical related disciplines. Dr. Alex Kharazi is a distinguished expert on cell therapy and immunotherapy. He has been a faculty member at the University of Southern California in Los Angeles and Chief Scientist at an Immunotherapy Laboratory......

Press Conference of Jiuzhitang Qihang Fund’s Investment in Stemdica Cell Technologies, Inc.
Jiuzhitang Maker was officially awarded Certificate of Zhongguancun High Technology Enterprise.
Jiuzhitang Maker signed the Cooperation Agreement on Jointly Building Jiuzhitang-ALTACO International Medical center for Stem Cells with Kazakhstan-based LLP "ALTACO-XXI" in the China-Kazakhstan Horgos Frontier International Cooperation Center.
New Progress Achieved in Jiuzhitang M&A Fund’s Investment in Stem Cell Business
Jiuzhitang Maker selected as one of the Ten Key companies received “Comprehensive Service Package” offered by Daxing District
Stem cell drugs formulated with Stemedica’s products approved in Kazakhstan for treatment of acute myocardial infarction
Jiuzhitang Maker signed cooperation agreements with Novastem from Mexico and ALTACO from Kazakhstan
Jiuzhitang Maker signed the Agreement on Co-construction of Stem Cells Clinical Research Base with Beijing Tiantan Hospital.
Jiuzhitang Maker’s manufacturing facility in Daxing District passed acceptance check

Company News